

# ISPOR 8<sup>TH</sup> ANNUAL EUROPEAN CONGRESS

## 6-8 NOVEMBER 2005 | PALAZZO DEGLI AFFARI | FLORENCE, ITALY

### ISPOR Short Courses

#### SATURDAY, 5 NOVEMBER

##### ALL DAY COURSE 9:00-18:00

###### Pharmacoeconomics / Economic Methods

###### Pharmacoeconomics for the Health Care Decision-Maker

**Faculty:** Ralph Crott PhD, MPH, Health Economist, Health Care Knowledge Center, Brussels, Belgium

**Course Description:** This one-day short course is designed to teach clinicians and new researchers how to incorporate pharmacoeconomic evaluations into study design and data analysis. Participants will learn how to collect and calculate the costs and outcomes of different alternatives, and determine the economic impact of clinical outcomes. The development of prospective and retrospective economic protocols and data collection sheets will be discussed. Different modeling techniques will be demonstrated and practiced in case studies. Timing of pharmacoeconomic evaluations in the drug development process will thereby receive special attention. Guidelines for optimal conduct of these studies will be demonstrated and their practical application will be discussed. From the decision-maker's viewpoint, the way pharmacoeconomic evaluations can be used in health care policy is demonstrated with real cases. *This course is suitable for those with little or some experience in the design, collection and analysis of pharmacoeconomic data.*

##### MORNING COURSES 9:00-13:00

###### Quality of Life / Patient-Reported Outcomes / Preference-based Methods

###### Analysis and Interpretation of Quality of Life and Patient-Reported Outcomes

**Faculty:** Linda Abetz MA, Director, Questionnaire Development and Validation, Mapi Values, Bollington, Cheshire, UK; Christine de la Loge, Director, Psychometrics and Statistics, Mapi Values, Lyon, France  
**Course Description:** This course is designed to provide a range of methods that may help to solve common problems encountered with quality of life / patient-reported outcomes. These include an overview of psychometric validation methods (including a brief overview of Rasch analysis), missing data analysis techniques, and a variety of methods to assess minimally clinically important differences. This course includes a discussion of the ISPOR co-developed report: "Incorporating The Patient's Perspective Into Drug Development And Communication Report" as well as the Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: Report of the ISPOR Task Force for Translation and Cultural Adaptation. Specific examples will be used throughout the course and participants will be asked to complete a short exercise. *This course is designed for individuals with little experience with quality-of-life studies.*

###### Real World Data Methods

###### European Databases and Retrospective Database Analysis

**Faculty:** TBA

**Course Description:** Large administrative claims databases provide a unique opportunity to examine retrospectively the effects of drug use on clinical and economic outcomes in "real world" settings. This course will cover an overview of databases available in Europe and compare key elements of these databases. This course will cover a discussion of the ISPOR Checklist for Retrospective Database Studies - Report of the ISPOR Task Force on Retrospective Databases and selected topics related to sampling, bias, and analysis. *This course is designed for those with little experience with European databases and database analysis.*

##### AFTERNOON COURSES 14:00-18:00

###### Pharmacoeconomic / Economic Methods

###### Cost Estimation and Assessing Financial (Budget) Impact of New Health Care Technologies

**Faculty:** Josephine Mauskopf PhD, Global Head, Health Economics and Outcomes Strategy, RTI Health Solutions, Research Triangle Park, NC, USA; C. Daniel Mullins PhD, Professor and Chair of Pharmaceutical Health Services Research, University of Maryland, School of Pharmacy, Baltimore, MD, USA

**Course Description:** This course will describe methods to determine the costs associated with a health condition and the budget impact of new technologies for that condition. The course will present incidence

and prevalence-based costing strategies. Treatment algorithms and event-based approaches will be demonstrated for disease-specific costs from the different decision-maker perspectives. Both static and dynamic methods for estimating the budget impact of adding a new drug to a health plan formulary will be presented. Issues related to imputing missing data will also be discussed. *This course is designed for those with some experience with pharmacoeconomic analysis.*

###### Modeling

###### Pharmacoeconomic Modeling

**Faculty:** Uwe Siebert MD, MPH, MSc, ScD, Professor of Public Health; Head of the Department of Public Health, Medical Decision Making and Health Technology Assessment, University of Health Sciences, Medical Informatics and Technology, Hall/Innsbruck, Austria, and Associate Professor of Radiology, Harvard Medical School, Director of the Cardiovascular Research Program, Institute for Technology Assessment, Massachusetts General Hospital, Boston, MA, USA; Gaby Sroczynski MPH, Decision Scientist, Institute for Technology Assessment, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA and Bavarian Public Health Research and Coordinating Center, University of Munich, Munich, Germany

**Course Description:** This course will present an in-depth discussion of advanced pharmacoeconomic modeling techniques such as Monte Carlo analysis, Markov modeling, and probabilistic sensitivity analysis including a review of the ISPOR Principles of Good Practice for Decision Analytic Modeling in Health Care Evaluations. *This course is designed for those with intermediate to advanced experience with modeling techniques.*

#### SUNDAY, 6 NOVEMBER

##### MORNING COURSES 8:00-12:00

###### Use of Pharmacoeconomics / Economic / Outcomes Research Information

###### Elements of Pharmaceutical Pricing

**Faculty:** Jack Mycka, President, Optimar Strategic Consulting LLC, Montclair, NJ, USA; Renato Dellamano PhD, President, ValueVector (Value Added Business Strategies), Milan, Italy

**Course Description:** This course is designed to cover the elements of pharmaceutical pricing decisions. It will cover the issues, information and processes employed and the role of pharmacoeconomics in helping to shape pricing decisions. *This course will be interactive and is designed for those with some experience in either pharmacoeconomics or pharmaceutical pricing.*

###### Pharmacoeconomic / Economic Methods

###### Transferability of Cost-Effectiveness Data between Countries

**Faculty:** Michael Drummond PhD, Director, University of York, Centre for Health Economics, York, UK

**Course Description:** Although the number of countries requiring an economic dossier as part of the submission dossier for public reimbursement of new drugs is growing, the pharmaceutical industry cannot conduct economic evaluations in every potential market. Clinical trials are increasingly done in international settings in order to quickly recruit a sufficient number of patients and to have at least some economic data from multiple countries. However, national decision-makers require country-specific or region-specific data on health care costs and are only willing to accept foreign data or international data when they are translated to their own specific setting. Guidelines on how to do this do not exist. This course starts with a discussion of factors that make economic data more difficult to transfer from one country to other countries than clinical data. Then we will review the methods that have been presented to offer a solution to this problem and their pros and cons. These methods include various types of regression-based methods and Markov models. *This course is for those with basic understanding of cost calculation and modeling.*

###### Use of Pharmacoeconomics / Economic / Outcomes Research Information

###### Health Care and Reimbursement Systems in Europe

**Faculty:** Gordon Carey, Cambridge Pharma Consultancy Ltd., Cambridge, UK

**Course Description:** This course will describe and compare various European health care systems, and will include information on health care financing and resource allocation mechanisms. Various issues encountered when defining benefit packages or introducing new health

care technology will be discussed. The course will also cover newer developments in European health care system organization and management, such as provision and purchaser-provider splits. This includes a discussion of the current role of health technology assessment and health economic analysis for reimbursement decisions in Europe. Participants will have the possibility to apply the taught course contents in a country-specific case study. *This course is designed for those with little experience with health care systems and reimbursement in Europe.*

###### Modeling

###### Bayesian Methods in Economic Evaluations

**Faculty:** Anthony O'Hagan PhD, Professor of Statistics, University of Sheffield, Sheffield, South Yorkshire, UK; Jeremy E. Oakley PhD, Lecturer, Department of Probability and Statistics, University of Sheffield, Sheffield, UK; John Williams Stevens BSc, Statistician, AstraZeneca, Leicestershire, UK

**Course Description:** This course is designed to provide an overview of the Bayesian approach and its application to health economics and outcomes research. The course will cover basic elements of Bayesian statistics, discuss differences between Bayesian and classical (frequentist) approaches, and demonstrate how to apply the Bayesian approach to clinical trials and cost-effectiveness analyses. Available software will be discussed, and examples of studies will be presented. *This course is for those with a basic appreciation of statistics and probability.*

###### Discrete Event Simulation for Economic Analyses

**Faculty:** J. Jaime Caro MDCM, FCRPC, FACP, Adjunct Professor of Medicine, Adjunct Professor of Epidemiology and Biostatistics, McGill University, Montreal PQ and Scientific Director, Caro Research Institute, Concord, MA, USA; Jürgen Möller MSc Mech Eng, Simulation Specialist, Caro Research Institute, Concord, MA, USA

**Course Description:** This course will provide a basic understanding of the key concepts of discrete event simulation. The focus will be on the use of these simulation models to address pharmacoeconomic (and device-related) problems. The course will be structured around practical exercises. Topics to be covered are: Why DES? Dynamic simulation as a tool; Components of a DES; How do you build a model? Modeling of processes and resource use; modeling of variables and decisions. It will address the ISPOR Task Force Reports on Good Research Practices - Modeling Studies / Cost-Effective Analysis alongside Clinical Trials. If time permits, simple animation will be demonstrated. We will use ARENA to build simple models. **Participants who wish to have hands-on experience should bring their laptops.** Instructors will distribute training versions of Arena. After the course the participants should understand how to interpret the results of a DES and have an understanding of simulation as a tool - how, where and when to use it. *The participants should also be able to map simple dynamic processes in ARENA and build simple models.*

###### Quality of Life / Patient-Reported Outcomes / Preference-based Methods

###### Utility Measurements (Preference-Based Techniques)

**Faculty:** Jan Busschbach PhD, Senior Investigator, Department for Medical Psychology and Psychotherapy, Erasmus University Medical Center, Rotterdam, The Netherlands; Ely Stolk MSc, Institute for Medical Technology Assessment (iMTA), Erasmus University Medical Center Rotterdam, The Netherlands

**Course Description:** Utility measurement is a method of determining an individual's preference for certain outcomes represented by a quantitative score (utility). During this course, methods for measuring preference-based outcomes like the standard gamble, time trade-off, and visual analogue scale will be demonstrated. Utility measurement however is not only about mastering these techniques; it is about using them in such a way that health care decision-makers can apply the results, for instance in QALY-analyses. For this purpose, one needs to be aware of shortcomings of the available utility measures and potential solutions. Furthermore one should be aware of the decision-making context and the way results are interpreted. To equip participants with expertise in the field of utility measurement, the most important issues will be discussed: for instance, we will consider the potential insensitivity of generic instruments for particular disease-specific problems, and discuss to what extent adaptation of generic or disease-specific quality of life instruments may offer a solution. This will be demonstrated with an exercise. Also the issue of "whose values count: patient values or values from the general public?" will be discussed. Finally we turn to the interpretation in the context of resource allocation. *This course is for those with some experience with quality-of-life measures in health economic evaluation.*

# ISPOR 8<sup>TH</sup> ANNUAL EUROPEAN CONGRESS

6-8 NOVEMBER 2005  
PALAZZO DEGLI AFFARI,  
FLORENCE, ITALY

## PROGRAM

EARLY REGISTRATION DEADLINE: 4 OCTOBER 2005

### Meeting Committee Co-chairs

#### PROGRAM PLANNING AND CONTRIBUTED RESEARCH REVIEW COMMITTEE CO-CHAIRS:

**Patrizia Berto PharmD, MBA**, President, PBE Consulting, Verona, Italy  
**Lorenzo Montovani MSc, DSc**, Director, Center of Pharmacoeconomics,  
School of Pharmacy, University of Napoli, Napoli, Italy

#### CONTRIBUTED WORKSHOP COMMITTEE CO-CHAIRS:

**Ovidio Brignoli MD**, Vice President, Italian Society of General Practice,  
Brescia, Italy  
**Claude LePen PhD**, Professor of Health Economics, Université Paris-  
Dauphine, Paris, France

#### CONTRIBUTED ISSUES PANEL COMMITTEE CO-CHAIRS:

**Cristina Negrini BSc**, Director, PBE Consulting, Milan, Italy  
**Andrea Messori PharmD**, Director, Laboratory of Pharmacoeconomics, Italian  
Society of Hospital Pharmacy, Florence, Italy

#### ROUNDTABLE DISCUSSIONS CO-CHAIRS:

**Mandy Ryan PhD**, Professor in Health Economics, Director of the Valuation and  
Implementation Programme, Health Economics  
Research Unit, University of Aberdeen, UK  
**Paul Kind MPhil**, Senior Research Fellow,  
Centre for Health Economics, University of York, UK



More than 600 research posters will  
be presented during three sessions

#### Poster Session I: Sunday, 6 November

Set Up: 11:30-12:00  
Poster Display Hours: 12:00-20:00  
Author Presentation Hour: 18:00-19:00  
Dismantle: 20:00-20:30

#### Poster Session II: Monday, 7 November

Set Up: 7:30-8:00  
Poster Display Hours: 8:00-20:00  
Author Presentation Hour: 18:00-19:00  
Dismantle: 20:00-20:30

#### Poster Session III: Tuesday, 8 November

Set Up: 7:30-8:00  
Poster Display Hours: 8:00-16:00  
Author Presentation Hour: 12:00-13:00  
Dismantle: 16:00-16:30

**RECORD  
NUMBER  
of abstracts  
submitted!**

#### CONGRESS LOCATION

Firenze Fiera S.p.A., Piazza Auda, 1, 50123 Firenze,  
Italy (Next to the Santa Maria Novella Train Station)

#### TRANSPORTATION

By plane, train, or car Florence is truly in the heart of Italy and  
Europe. **Airport:** The Amerigo Vespucci International Airport  
(IATA Code: FLR), located only 4 km from the city center.

**Train:** Florence is well connected to European cities by train.  
Train station is the Santa Maria Novella Train Station.



#### HOTEL INFORMATION

Visit the ISPOR website for a listing of nearby hotels and location at:  
[http://www.ispor.org/congresses/italy1105/Florence\\_hotels.asp](http://www.ispor.org/congresses/italy1105/Florence_hotels.asp)

- Print and complete the ISPOR 8th Annual European Congress Hotel Reservation Form at [http://www.ispor.org/congresses/italy1105/Florence\\_Hotel\\_Reservation\\_Form.pdf](http://www.ispor.org/congresses/italy1105/Florence_Hotel_Reservation_Form.pdf) and fax to: +39 055 587189 or
  - Email your contact information, hotel preference and method of payment to: [Isabelle@promhotels.it](mailto:Isabelle@promhotels.it) or
  - Call: +39 055 553941 or
  - Use the PromHotel website at: [https://secure.dada.it/promhotels/booking/eventi\\_congressi.php?a=form&id=57](https://secure.dada.it/promhotels/booking/eventi_congressi.php?a=form&id=57)
- Reservations through PromHotel must be made by **AUGUST 30, 2005**.

#### SPECIAL EVENT

You are invited to attend **The ISPOR 10th Anniversary Party**  
Vincigliata Castle, Feisole, Italy  
Monday, 7 November 2005 from 20:00-23:30  
WINE TASTING • DINNER BUFFET • MUSIC & DANCING (reg. req'd.)

# ISPOR 8<sup>TH</sup> ANNUAL EUROPEAN CONGRESS

6-8 NOVEMBER 2005 | PALAZZO DEGLI AFFARI | FLORENCE, ITALY

## Program

### “INCORPORATING VALUES INTO HEALTH CARE DECISIONS”

#### SATURDAY, 5 NOVEMBER 2005

9:00-13:00 PRE-CONGRESS SHORT COURSES

14:00-18:00 PRE-CONGRESS SHORT COURSES

#### SUNDAY, 6 NOVEMBER 2005

8:00-12:00 PRE-CONGRESS SHORT COURSES

12:00-13:00 GRAND OPENING & CONTRIBUTED RESEARCH POSTER VIEWING - SESSION I (Over 200 posters)

13:00-13:30 WELCOME FROM THE ISPOR PRESIDENT

**Peter Neumann ScD**, ISPOR 2005-2006 President & Associate Professor of Policy and Decision Sciences, Harvard School of Public Health, Boston, MA, USA

#### INTRODUCTION AND CONGRESS OBJECTIVES

**Patrizia Berto PharmD, MBA**, Program Co-chair & President, PBE Consulting, Verona, Italy; **Lorenzo Mantovani MSc, DSc**, Program Co-chair & Director, Center of Pharmacoeconomics, School of Pharmacy, University of Napoli, Napoli, Italy

#### ISPOR 10 YEARS - PAST, PRESENT AND FUTURE

**Marilyn Dix Smith PhD**, Founding Executive Director, ISPOR, Lawrenceville, NJ, USA

13:30-15:00

**FIRST PLENARY SESSION - PATIENT VALUES AND SOCIETAL VALUES: HOW TO MEASURE AND COMPARE OUTCOMES AND WHAT CONSIDERATIONS FOR THE DIFFERENT AUDIENCES**

The value of health from a patient's perspective (better QoL, less side-effects) versus value of health from a society's perspective (general morbidity, mortality) will be discussed. This translates into different messages for different audiences (payers, physicians, patient associations, individuals).

**Speakers:** **Paul Kind MPhil**, Principal Investigator, Centre for Health Economics, University of York, York, UK; **Mandy Ryan PhD**, Professor in Health Economics & Director of the Valuation and Implementation Programme, Health Economics Research Unit, University of Aberdeen, Aberdeen, UK; **Claude Le Pen PhD**, Scientific Director, Aramis Consultants, Neuilly Sur Seine, France

15:00-15:30 Break

15:30-16:30 CONTRIBUTED WORKSHOPS-SESSION I

#### W1: EXPOSURE PROPENSITY SCORES: CONCEPTS, APPLICATIONS, AND PRACTICAL CONSIDERATIONS

**DL: Almut G Winterstein PhD**, Pharmacy Health Care Administration, University of Florida, Gainesville, FL, USA; **Abraham G Hartzema MSPH, PhD**, Dept. of Pharmacy Health Care Administration, University of Florida, Gainesville, FL, USA; **Jonathan J Shuster PhD**, Department of Health Policy and Epidemiology, Division of Biostatistics, University of Florida, Gainesville, FL, USA; **Tobias Gerhard BS**, Pharmacy Health Care Administration, University of Florida, Gainesville, FL, USA

#### W2: METHODS FOR MEDICATION COMPLIANCE STUDIES: PATIENT COMPLIANCE AS A PREDICTOR OF CLINICAL AND ECONOMIC OUTCOMES

**DL: Michael Nichol PhD**, University of Southern California, Dept. of Pharm Econ & Policy, Los Angeles, CA, USA; **Femida Gwadry-Sridhar PharmD, PhD**, McMaster University, London, ON, Canada; **JB Benner PharmD, ScD**, ValueMedics Research, Falls Church, VA, USA; **Joyce Cramer**, Yale University School of Medicine, West Haven, CT, USA

#### W3: METHODS FOR PRESENTING PROBABILISTIC SENSITIVITY ANALYSES FOR EFFECTIVE COMMUNICATION OF FINDINGS

**DL: Douglas CA. Taylor MBA**, Health Economics & Outcomes Research, Innovus Research (U.S.) Inc, Medford, MA, USA; **Lisa J. McGarry MPH**, Health Economics & Outcomes Research, Innovus Research (U.S.) Inc, Medford, MA, USA; **David Thompson PhD**, Health Economics & Outcomes Research, Innovus Research (U.S.) Inc, Medford, MA, USA

#### W4: CASE STUDIES IN PERSONALIZED MEDICINE: VALUE CREATION AND REWARDS-INCENTIVES AND IMPLICATIONS

**DL: Louis Garrison PhD**, Department of Pharmacy, University of Washington, Seattle, WA, USA; **Adrian Towse MA**, Office of Health Economics, London, UK; **David L Veenstra MD**, University of Washington, Department of Pharmacy, Seattle, WA, USA

#### W5: MULTI-NATIONAL ASSESSMENT OF OUTCOMES VIA RETROSPECTIVE DATABASES

**DL: Vittorio Maio PharmD, MSPH**, Department of Health Policy, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA, USA; **Elaine J. Yuen PhD, MBA**, Center for Research in Medical Education and Health Care, Jefferson Medical College, Thomas Jefferson University,

Philadelphia, PA, USA; **Diana Brixner PhD**, Pharmacotherapy Outcomes Research Center, University of Utah College of Pharmacy, Salt Lake City, UT, USA; **Gary M Oderda PharmD, MPH**, Pharmacotherapy Outcomes Research Center, University of Utah College of Pharmacy, Salt Lake City, UT, USA; **Sebastian Schneeweiss MD, ScD**, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital / Harvard Medical School, Boston, MA, USA

#### W6: A NEW APPROACH TO HTA - A COMPUTERIZED MODEL

**DL: Ifat Abadi-Korek PhD**, Israeli Center for Technology Assessment in Health Care (ICTAHC), The Gertner Institute for Epidemiology & Health Policy Research, Ramat Gan, Israel; **Orly Tamir MSc**, Health Technology Assessment & Research, Israeli Center for Technology Assessment in Health Care (ICTAHC), The Gertner Institute for Epidemiology & Health Policy Research, Ramat Gan, Israel; **Alon Seifan MSc**, Israeli Center for Technology Assessment in Health Care (ICTAHC), The Gertner Institute for Epidemiology & Health Policy Research, Ramat Gan, Israel; **Ishay Ostfeld MD**, Israeli Center for Technology Assessment in Health Care (ICTAHC), The Gertner Institute for Epidemiology & Health Policy Research, Ramat Gan, Israel; **Joshua Shemer MD**, Israeli Center for Technology Assessment in Health Care (ICTAHC), The Gertner Institute for Epidemiology & Health Policy Research, Ramat Gan, Israel

#### W7: DISCRETE CHOICE EXPERIMENTS IN HEALTH POLICY AND DECISION MAKING

**DL: Mandy Ryan MSc, PhD**, Health Economics Research Unit, Aberdeen University, Aberdeen, UK; **Mark Sculpher PhD**, Centre for Health Economics, University of York, Heslington, York, UK; **Lorenzo G. Mantovani EconD, MSc, DSc**, Center of Pharmacoeconomics, University of Milan, Milan, Italy; **Andrea Bracco MSc**, Novartis Pharma AG, Basel, Switzerland

#### W8: WHAT REALLY ARE PATIENT-REPORTED OUTCOMES?

**DL: Judith Barr MEd, ScD**, Northeastern University, National Education and Research Center for Outcomes Assessment, Boston, MA, USA; **Laurie Burke RPh, MPH**, Food and Drug Administration, Rockville, MD, US; **Pennifer Erickson PhD**, O.L.G.A., State College, PA, USA

16:30-17:00 Break

17:00-18:00 CONTRIBUTED RESEARCH PODIUM PRESENTATIONS - SESSION I (16 presentations)

#### Development Of Methods And Concepts In Outcomes Research Statistics

##### MC1 USE OF A MODIFIED RECURSIVE PARTITIONING AND AMALGAMATION (RECPAM) TECHNIQUE IN OUTCOMES RESEARCH

**Katz LM<sup>1</sup>, Doyle JJ<sup>1</sup>, Bergemann R<sup>2</sup>, Siegartel LR<sup>1</sup>, Stern L<sup>1</sup>, Chalfin D<sup>3</sup>, Danis M<sup>4</sup>, Rapoport J<sup>5</sup>, Levy M<sup>6</sup>, <sup>1</sup>Analytica International, New York, NY, USA; <sup>2</sup>Analytica International, Loerrach, Germany; <sup>3</sup>Montefiore Medical Center, Port Washington, NY, USA; <sup>4</sup>National Institutes of Health, Bethesda, MD, USA; <sup>5</sup>Mount Holyoke College, South Hadley, MA, USA; <sup>6</sup>Brown University, Providence, RI, USA**

##### MC2 IMPACT OF THE PROPENSITY SCORE ESTIMATION METHOD WHEN MATCHING PATIENTS TO REDUCE RECRUITMENT BIAS IN OBSERVATIONAL STUDIES

**Riou Franca L, Payet S, Le Lay K, Launois R, REES France, Paris, France**

##### MC3 METAMODELLING FOR THE CALCULATION OF THE EXPECTED VALUE OF PERFECT INFORMATION ON INDIVIDUAL MODEL PARAMETERS

**Oostenbrink JB, Rutten-van Molken MP, Erasmus MC, Rotterdam, The Netherlands**

##### MC4 UNCONDITIONAL POWER FOR SECONDARY OBJECTIVES IN A CLINICAL TRIAL

**Wang J, Irish WD, RTI Health Solutions, Research Triangle Park, NC, USA**

#### Cost Evaluation Studies In Cardiovascular Diseases

##### CV1 ATRIAL BASED PACING DECREASES ATRIAL FIBRILLATION RELATED HOSPITALIZATIONS AND COSTS IN BRADY-TACHY SYNDROME

**Ruciński P<sup>1</sup>, Kutarski A<sup>1</sup>, Latek M<sup>2</sup>, Kamiński B<sup>2</sup>, Szczasny M<sup>1</sup>, Widomska-Czekajska T<sup>1</sup>, Wdowiak L<sup>1</sup>, <sup>1</sup>Medical University of Lublin, Lublin, Lubelskie, Poland; <sup>2</sup>Warsaw School of Economics, Warszawa, Mazowieckie, Poland**

##### CV2 COSTS OF CARDIOVASCULAR DISEASE: A CASE-CONTROL STUDY

**De Portu S<sup>1</sup>, Monzini M<sup>2</sup>, Mazzarotto E<sup>3</sup>, Galletti M<sup>3</sup>, Mantovani LG<sup>2</sup>, <sup>1</sup>University of Naples, Naples, Italy; <sup>2</sup>Center of Pharmacoeconomics, Milan, Italy; <sup>3</sup>University of Naples, Naples, Italy**

##### CV3 A COST-EFFECTIVENESS ANALYSIS OF CANDESARTAN IN THE TREATMENT OF CHRONIC HEART FAILURE

**Lamotte M<sup>1</sup>, Annemans L<sup>1</sup>, Schockaert B<sup>2</sup>, <sup>1</sup>IMS Health, Brussels, Belgium; <sup>2</sup>Astrazeneca, Brussels, Belgium**

##### CV4 DISCRETE EVENT SIMULATION OF THE ECONOMIC CONSEQUENCES OF ADDING MANAGED VENTRICULAR PACING MODE (DDDR-MVP) TO A STANDARD DUAL CHAMBER PACEMAKER (DDDR) IN FRANCE

**Deniz HB, Caro JJ, Ward AJ Caro Research Institute, Concord, MA, USA**

\* DL = Discussion Leaders

## Utility-Based Patient-Reported Outcomes

### UB1 MAPPING FROM DISEASE SPECIFIC MEASURES TO UTILITY: ALGORITHMS FOR ESTIMATING EQ-5D AND SF-6D VALUES FROM THE INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE IN PATIENTS WITH CROHN'S DISEASE

Buxton M<sup>1</sup>, Lacey L<sup>2</sup>, Niecko T<sup>3</sup>, Miller D<sup>4</sup>, Townsend R<sup>1</sup>, <sup>1</sup>Brunel University, Uxbridge, UK; <sup>2</sup>Lacey Solutions Ltd, Co Dublin, Ireland; <sup>3</sup>Niecko Health Economics, Escondido, CA, USA; <sup>4</sup>Elan Pharmaceuticals, San Diego, CA, USA

### UB2 QUANTIFYING THE RELATIONSHIP BETWEEN DISEASE SEVERITY, UTILITY AND HEALTH CARE RESOURCE USE IN CROHN'S DISEASE

Weston AR<sup>1</sup>, Gibson PR<sup>2</sup>, Florin T<sup>3</sup>, Macrae F<sup>4</sup>, Radford-Smith G<sup>5</sup>, Shann A<sup>6</sup>, Lawrance I<sup>7</sup>, <sup>1</sup>Health Technology Analysts Pty Ltd, Sydney, NSW, Australia; <sup>2</sup>Box Hill Hospital, Box Hill, VIC, Australia; <sup>3</sup>Mater Health Services Adult Hospital, Brisbane, QLD, Australia; <sup>4</sup>The Royal Melbourne Hospital, Melbourne, VIC, Australia; <sup>5</sup>Royal Brisbane Hospital, Brisbane, QLD, Australia; <sup>6</sup>Schering-Plough, Sydney, NSW, Australia; <sup>7</sup>Fremantle Hospital, Fremantle, WA, Australia

### UB3 A COMPARISON OF THE EQ-5D AND THE SF-6D IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION

Brown MC, Pfizer Limited, Sandwich, Kent, UK

### UB4 DETERMINANTS OF HEALTH STATE UTILITY IN PATIENTS WITH PSORIATIC ARTHRITIS

Anis AH<sup>1</sup>, Guh D<sup>2</sup>, Bansback NJ<sup>2</sup>, Melilli LE<sup>2</sup>, <sup>1</sup>University of British Columbia, Vancouver, BC, Canada; <sup>2</sup>Centre for Health Evaluation and Outcome Sciences, Vancouver, BC, Canada; <sup>3</sup>Abbott Laboratories, Abbott Park, IL, USA

## Cost Evaluation Studies In Urologic And Hematologic Diseases

### UH1 COST AND QUALITY OF LIFE OF HEMOPHILIA: COMPARISON BETWEEN PATIENTS WITH AND PATIENTS WITHOUT INHIBITORS

Scalone L<sup>1</sup>, Gringeri A<sup>2</sup>, Mannucci PM<sup>2</sup>, Von Mackensen S<sup>3</sup>, Mantovani LG<sup>1</sup>, <sup>1</sup>Center of Pharmacoeconomics, Milan, Italy; <sup>2</sup>Haemophilia and Thrombosis Centre, Milan, Italy; <sup>3</sup>Institute for Medical Psychology, Hamburg, Germany

### UH2 COST DRIVERS IN MULTIPLE MYELOMA TREATMENT - A 2 YEAR ANALYSIS FROM A MULTICOUNTRY RETROPROJECTED CHART REVIEW

Moeremans K<sup>1</sup>, Caekelbergh K<sup>1</sup>, Spaepen E<sup>1</sup>, Annemans L<sup>1</sup>, Dhawan R<sup>2</sup>, <sup>1</sup>IMS Health, Brussels, Belgium; <sup>2</sup>Johnson & Johnson Pharmaceutical Services LLC, Raritan, NJ, USA

### UH3 OVERACTIVE BLADDER IN MALES: A GROWING HEALTH AND ECONOMIC BURDEN

Reeves P<sup>1</sup>, Kopp Z<sup>2</sup>, Milsom J<sup>3</sup>, Artibani W<sup>4</sup>, Abrams P<sup>5</sup>, <sup>1</sup>Fourth Hurdle Consulting Ltd, London, UK; <sup>2</sup>Pfizer Inc, New York, NY, USA; <sup>3</sup>Sahlgrenska University Hospital, Göteborg, Sweden; <sup>4</sup>Monoblocco Ospedaliero, Padova, Italy; <sup>5</sup>Bristol Urological Institute, Bristol Avon, UK

### UH4 CHARACTERISTICS RELATED TO PRODUCTIVITY LOSS IN PATIENTS WITH OVERACTIVE BLADDER: RESULTS FROM THE MATRIX STUDY

Pizzi LT<sup>1</sup>, Gemmen E<sup>2</sup>, Dahl NV<sup>3</sup>, <sup>1</sup>Jefferson Medical College, Philadelphia, PA, USA; <sup>2</sup>Quintiles, Falls Church, VA, USA; <sup>3</sup>Watson Laboratories, Morristown, NJ, USA

## 18:00-20:00 EXHIBITORS' OPEN HOUSE RECEPTION, RESEARCH POSTER PRESENTATIONS - SESSION I & ISPOR 10th ANNIVERSARY CELEBRATION



## MONDAY, 7 NOVEMBER 2005

### 7:30-8:45 ROUND TABLE BREAKFAST DISCUSSIONS

### 8:00-9:00 CONTRIBUTED RESEARCH POSTER PRESENTATIONS - SESSION II VIEWING (Over 200 posters)

### 9:00-10:30 SECOND PLENARY SESSION HEALTH CARE DECISION MAKERS FACING THE BUDGET ALLOCATION DILEMMA: COMPRESSING MORTALITY VS. COMPRESSING MORBIDITY

An aging population and the challenge for decision-makers to fund traditional therapies aimed at reducing mortality from chronic (eg cardiovascular, diabetes) diseases while still saving room for reducing morbidity with emerging expensive treatments will be discussed.

**Speaker: Dr. Claudio Cricelli**, President, Società Italiana di Medicina Generale, Firenze, Italy

### 10:30-10:45 Break Coffee Sponsored by: Caro Research

### 10:45-11:45 CONTRIBUTED WORKSHOPS-SESSION II

### W9: META-ANALYSIS OF LONGITUDINAL DATA FOR ECONOMIC MODELS: AN APPLICATION OF MULTI-OUTCOME MODELS

DL: **Khajak J Ishak MSc**, Caro Research Institute, Montreal, QC, Canada; **Robert W. Platt PhD**, Department of Pediatrics & Epidemiology and Biostatistics, McGill University, Montreal, QC, Canada; **J. Jaime Caro MD**, Caro Research Institute, Concord, MA, USA

### W10: INCORPORATING MEASURES OF COMPLIANCE & PERSISTENCE IN PHARMACOECONOMIC EVALUATIONS

DL: **Dyfrig Hughes PhD**, Centre for the Economics of Health, University of Wales, Bangor, UK; **Warren Cowell MSc**, Roche Products Ltd, Welwyn Garden City, Hertfordshire, UK; **Tamas Andras Koncz MD**, Outcomes Research and Evidence Based Medicine, Pfizer Ltd, Tadworth, Surrey, UK

### W11: THE ADDED VALUE OF BAYESIAN BELIEF NETWORKS FOR DECISION MAKING

DL: **G Baio PhD**, Department of Statistical Science, University College London, London, UK; **JP Jansen PhD**, MAPI Values, Houten, The Netherlands

### W12: MIXED TREATMENT COMPARISONS

DL: **Neil Stephen Hawkins MSc**, Centre for Health Economics, University of York, Heslington, York, UK; **Mark J Sculpher MSc, PhD**, Centre for Health Economics, University of York, Heslington, York, UK;

\* DL = Discussion Leaders

**Steve Palmer MSc**, Centre for Health Economics, University of York, Heslington, York, UK

### W13: PRICING POTENTIAL OF A NEW DRUG: APPLICATION OF THE PRICING MATRIX MODEL

DL: **Mark JC Nuijten PhD, MD, MBA**, Erasmus University, Rotterdam, The Netherlands

### W14: KEY ISSUES IN MARKET ACCESS: FRANCE, SPAIN, AND ITALY

DL: **Claude LePen PhD**, Arenis Consultants, Neuilly sur Seine, France; **Annie Chicoye PhD**, Arenis Consultants, Neuilly sur Seine, France; **Xavier Badia MD, PhD**, Health Outcomes Research Europe, Avda. Diagonal, Barcelona, Spain; **Regina Múzquiz PhD**, Sanofi-Aventis, Madrid, Spain; **Enrico Miceli PhD**, Novartis Farma SpA, Rome, Italy; **Cristina Negri BSc**, Pbe Consulting, Milan, Italy

### W15: CONJOINT ANALYSIS: APPLICATION TO GLOBAL PRICING AND REIMBURSEMENT STRATEGY

DL: **F. Reed Johnson PhD**, RTI Health Solutions, Research Triangle Park, NC, USA; **Deirdre M Mladsji BA**, RTI Health Solutions, Research Triangle Park, NC, USA; **Keiron Sparrowhawk MSc, MBA**, PriceSpective Ltd, Buntingford, UK; **Nigel Gregson BA**, PriceSpective LLC, Bluebell, PA, USA

### W16: THE USE OF COMPOSITE ENDPOINTS: A REVIEW OF THE REGULATORS PERSPECTIVE AND METHODOLOGICAL ISSUES

DL: **Christine De la Loge MSc**, Mapi Values, Lyon, France; **Benoit Arnould MSc, MA**, Mapi Values, Lyon, France; **Nadia Cadi Soussi MA**, Lyon, France; **Khalid Errabi MA**, MAPI Values, Lyon, France

## 11:45-13:15 LUNCH, EXHIBITS AND CONTRIBUTED RESEARCH POSTER PRESENTATIONS - SESSION II (Over 200 posters)

## 13:15-14:15 CONTRIBUTED RESEARCH PODIUM PRESENTATIONS - SESSION II (16 presentations)

### Health Care Use And Policy: Focus On Health Professionals

**HP1 IDENTIFYING PREDICTORS OF OFF-LABEL UTILIZATION PATTERNS OF TWO BIOTECHNOLOGY DRUGS, RECOMBINANT ERYTHROPOIETIN ALFA AND DARBEPOETIN ALFA: A MULTI-HOSPITAL STUDY**  
Patkar AD, Holdford DA, Peterson SP, Virginia Commonwealth University, Richmond, VA, USA

**HP2 PHARMACIST RESPONSE TO COMPUTER-GENERATED DRUG THERAPY ALERTS IN A LONG TERM CARE SETTING**

Wegner S<sup>1</sup>, Trygstad T<sup>2</sup>, Christensen DB<sup>2</sup>, <sup>1</sup>AccessCare, Inc, Morrisville, NC, USA; <sup>2</sup>University of North Carolina, Chapel Hill, NC, USA

**HP3 PHYSICIAN PRESCRIBING OF SLEEP DISORDER MEDICATIONS IN UNITED STATES OUTPATIENT SETTINGS: FACTORS AFFECTING PRESCRIPTION OF HIGH ABUSE POTENTIAL AND COSTLY MEDICATIONS**  
Rasu R<sup>1</sup>, Balkrishnan R<sup>2</sup>, Shenolikar R<sup>2</sup>, Nahata M<sup>2</sup>, <sup>1</sup>University of Missouri, Kansas City, Kansas City, MO, USA; <sup>2</sup>Ohio State University College of Pharmacy, Columbus, OH, USA

### HP4 PRIMARY CARE AND GATEKEEPER MODELS IN GERMANY - WHAT DO THE PATIENTS WANT?

Kielhorn H<sup>1</sup>, Wolter AB<sup>1</sup>, Schoenermark MP<sup>2</sup>, <sup>1</sup>Schoenermark, Kielhorn and Collegen, Hannover, Germany; <sup>2</sup>Hannover Medical School, Hannover, Germany

### Methods And Concepts In Patient-Oriented Research

### PO1 TRAJECTORIES OF EQ-5D QUALITY OF LIFE UTILITY SCORES FOR 10,000 SCHIZOPHRENIA OUTPATIENTS OVER 2 YEARS: A REPORT FROM THE SOHO STUDY

Hammond GC<sup>1</sup>, Croudace TJ<sup>1</sup>, Jones PB<sup>1</sup>, Belger M<sup>2</sup>, Novick D<sup>2</sup>, <sup>1</sup>University of Cambridge, Cambridge, UK; <sup>2</sup>Eli Lilly and Company Ltd, Windlesham, Surrey, UK

### PO2 DEVELOPMENT AND VALIDATION OF A QUESTIONNAIRE TO EVALUATE SEVERITY OF SYMPTOMS IN PATIENTS WITH IBS-C AND IBS-A

Pare P<sup>1</sup>, Lam SY<sup>2</sup>, Balshaw R<sup>3</sup>, Morin J<sup>4</sup>, Khorasheh S<sup>3</sup>, Barbeau M<sup>4</sup>, Kelly S<sup>1</sup>, Dastani H<sup>5</sup>, **McBurney C<sup>6</sup>**, <sup>1</sup>Centre Hospitalier affilié Universitaire de Québec, Québec, QC, Canada; <sup>2</sup>Hawse Clinic, Calgary, AB, Canada; <sup>3</sup>Syreon Corporation, Vancouver, BC, Canada; <sup>4</sup>Novartis Pharmaceuticals Inc (Canada), Dorval, QC, Canada; <sup>5</sup>Novartis Pharmaceuticals Corp, East Hanover, NJ, USA; <sup>6</sup>Novartis Pharma AG, Basel, Switzerland

### PO3 CLASSIFYING AND PREDICTING ANTIPSYCHOTIC ADHERENCE AMONG SCHIZOPHRENIA OUTPATIENTS IN EUROPE: A LATENT CLASS ANALYSIS

Croudace TJ<sup>1</sup>, Jones PB<sup>1</sup>, Hammond GC<sup>1</sup>, Brown J<sup>2</sup>, Shi L<sup>3</sup>, <sup>1</sup>University of Cambridge, Cambridge, UK; <sup>2</sup>Eli Lilly and Company Ltd, Windlesham, Surrey, UK; <sup>3</sup>Tulane University, New Orleans, LA, USA

### PO4 ESTIMATING QUALITY-ADJUSTED TIME WITHOUT SYMPTOMS OR TOXICITY USING A MULTIVARIATE FAILURE TIME REGRESSION MODEL

Wang J, **Sherrill B**, Irish WD RTI Health Solutions, Research Triangle Park, NC, USA

### Health Related Quality Of Life Based Patient Reported Outcomes

### QL1 DETERMINING THE MINIMALLY IMPORTANT DIFFERENCE OF THE OVERACTIVE BLADDER QUESTIONNAIRE (OAB-Q)

Coyne KS<sup>1</sup>, Matza L<sup>1</sup>, Kopp Z<sup>2</sup>, Jumadilova Z<sup>2</sup>, Thompson C<sup>1</sup>, Khullar V<sup>3</sup>, <sup>1</sup>The MEDTAP Institute at UBC, Bethesda, MD, USA; <sup>2</sup>Pfizer Inc, New York, NY, USA; <sup>3</sup>Imperial College, School of Medicine, London, UK

### QL2 TESTING THE CROSS-WALK: SALVAGING CANCER SPECIFIC MEASURES FOR USE IN ECONOMIC EVALUATION

Wilson TR<sup>1</sup>, Kind P<sup>2</sup>, <sup>1</sup>University of York, York, UK; <sup>2</sup>Outcomes Research Group, York, UK

### QL3 "FAMILIAL STUDY": ANALYSIS OF THE DIFFERENCES BETWEEN DIALYSIS PATIENTS AND THEIR CAREGIVERS (FAMILY CARERS, NURSES AND DOCTORS) ON DIALYSIS PATIENTS' HRQOL, AND OF THE FAMILY CARERS' HRQOL AND BURDEN

Alvarez-ude F<sup>1</sup>, **Rebollo P<sup>2</sup>**, Valdes C<sup>1</sup>, Estebanez C<sup>1</sup>, <sup>1</sup>Hospital General de Segovia, Instituto "Reina Sofia" for Nephrological Research, Segovia, Segovia, Spain; <sup>2</sup>Hospital Universitario Central de Asturias and Institute Reina Sofia for Nephrological Research, Oviedo, Asturias, Spain

### QL4 VARIABILITY IN QOL QUESTIONNAIRES AND THE HANDLING OF MISSING DATA IN PATIENTS WITH NON-SMALL CELL LUNG CANCER TREATED WITH CHEMOTHERAPY

Johnson LL<sup>1</sup>, Miller KL<sup>1</sup>, Miller DP<sup>1</sup>, Colwell HH<sup>1</sup>, Bhattacharyya SK<sup>2</sup>, Deeter RG<sup>2</sup>, **Mathias SD**, <sup>1</sup>Ovation Research Group, San Francisco, CA, USA; <sup>2</sup>Amgen, Inc, Thousand Oaks, CA, USA

Program continued inside...

# Program continued...

## Cost Evaluation Studies In Interventional Cardiology

### IC1 THE COST-EFFECTIVENESS OF DRUG-ELUTING STENTS BASED ON THE A SYNTHESIS OF THE RESULTS OF 15 RANDOMISED CONTROLLED TRIALS

Hawkins N, Sculpher M, University of York, York, UK

### IC2 PREDICTING THE COST-EFFECTIVENESS OF THE ABT-578 COATED DRIVER CORONARY STENT (ENDEAVOR) IN DE NOVO NATIVE CORONARY ARTERY LESIONS

Remák E<sup>1</sup>, Hutton J<sup>1</sup>, Oliver E<sup>2</sup>, Brasseur P<sup>3</sup>, <sup>1</sup>The MEDTAP Institute at UBC, London, UK; <sup>2</sup>Medtronic Ltd, Watford, UK; <sup>3</sup>Medtronic AG, Tolochenaz, Switzerland

### IC3 HEALTH ECONOMIC EVALUATION OF BIVALIRUDIN IN THE MANAGEMENT OF PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION IN BELGIUM

Ethgen O<sup>1</sup>, Lamotte M<sup>2</sup>, Annemans L<sup>2</sup>, <sup>1</sup>University of Liège, Liège, Belgium; <sup>2</sup>HEDM - IMS Health, Brussels, Belgium

### IC4 ECONOMIC ANALYSIS OF THE STRATEGY STUDY: TIROFIBAN AND DRUG ELUTING STENTS VERSUS ABCIXIMAB AND BARE METAL STENTS

Mittmann N<sup>1</sup>, Valgimigli M<sup>2</sup>, Percoco G<sup>3</sup>, Campo G<sup>3</sup>, Squasi P<sup>3</sup>, Arcozzi C<sup>3</sup>, Malagutti P<sup>3</sup>, Ferrari R<sup>3</sup>, Seung SJ<sup>4</sup>, Isogai P<sup>5</sup>, <sup>1</sup>Sunnybrook & Women's Health Science Centre, Toronto, ON, Canada; <sup>2</sup>University of Ferrara, Institute of Cardiology, Arcispedale S' Anna, Italy, Ferrara, Italy; <sup>3</sup>University of Ferrara, Institute of Cardiology, Arcispedale S' Anna, Ferrara, Italy, Italy; <sup>4</sup>HOPE Research Centre, Sunnybrook & Women's College Health Sciences Centre, Toronto, ON, Canada

14:15-14:30 **Break Coffee Sponsored by: Caro Research** 

### 14:30-15:30 CONTRIBUTED RESEARCH PODIUM PRESENTATIONS - SESSION III (16 presentations)

#### Health Care Use And Policy: Focus On Patients

### HP5 TREATMENT PATTERNS AMONG POSTMENOPAUSAL OSTEOPOROTIC WOMEN STARTING ON DAILY OR WEEKLY BISPHOSPHONATE THERAPY

Huybrechts KE<sup>1</sup>, Ishak KJ<sup>2</sup>, Proskorovsky I<sup>2</sup>, Caro JJ<sup>1</sup>, Levinton C<sup>1</sup>, <sup>1</sup>Caro Research, Concord, MA, USA; <sup>2</sup>Caro Research, Dorval, QC, Canada

### HP6 EFFECT OF CO-PAYMENT ON COMPLIANCE TO STATINS AFTER CORONARY HEART DISEASE HOSPITALIZATION

Ye X, St.Peter WL, Gross CR, University of Minnesota, Minneapolis, MN, USA

### HP7 ADHERENCE TO IMMUNOSUPPRESSIVE THERAPY IN PRIVATE PAYER TRANSPLANT RECIPIENTS

Lalla A<sup>1</sup>, Gilmore A<sup>1</sup>, Legorreta A<sup>2</sup>, <sup>1</sup>Health Benchmarks, Inc, Woodland Hills, CA, USA; <sup>2</sup>UCLA School of Public Health, Woodland Hills, CA, USA

### HP8 PATIENT CHARACTERISTICS, GLYCEMIC CONTROL, AND THE USE OF ANTIDIABETIC AGENTS AMONG INDIVIDUALS DIAGNOSED WITH TYPE-2 DIABETES: EVIDENCE FROM THE UK

Secnik K<sup>1</sup>, Yurgin N<sup>1</sup>, Lage MJ<sup>2</sup>, McDonald-Everett C<sup>1</sup>, <sup>1</sup>Eli Lilly and Company, Indianapolis, IN, USA; <sup>2</sup>HealthMetrics Outcomes Research, LLC, Groton, CT, USA

#### Health Related Quality Of Life Based Patient Reported Outcomes: Session 2

### QL5 CLINICAL RESPONSES TO TREATMENT AND CHANGES IN THE DERMATOLOGY LIFE QUALITY INDEX (DLQI) IN MODERATE TO SEVERE PLAQUE PSORIASIS PATIENTS TREATED WITH ADALIMUMAB

Shikhar R<sup>1</sup>, Thompson C<sup>2</sup>, Melilli LE<sup>3</sup>, <sup>1</sup>MEDTAP Institute at United Biosource Corporation, Seattle, WA, USA; <sup>2</sup>MEDTAP Institute at United Biosource Corporation, Bethesda, MD, USA; <sup>3</sup>Abbott Laboratories, Abbott Park, IL, USA

### QL6 ADALIMUMAB REDUCES FATIGUE IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS (AS) - 6-MONTH RESULTS OF A CANADIAN AS STUDY

Luo MP<sup>1</sup>, Revicki D<sup>2</sup>, Rentz A<sup>2</sup>, Wong RL<sup>3</sup>, Maksymowych WP<sup>4</sup>, <sup>1</sup>Abbott Laboratories, Abbott Park, IL, USA; <sup>2</sup>MEDTAP Institute at United Biosource Corporation, Bethesda, MD, USA; <sup>3</sup>Abbott Laboratories, Parsippany, NJ, USA; <sup>4</sup>University of Alberta Hospital, Edmonton, AB, Canada

### QL7 IMPACT OF LUTS ON QUALITY OF LIFE IN ITALIAN WOMEN

Prezioso D<sup>1</sup>, Zattoni F<sup>2</sup>, Pesce F<sup>3</sup>, Scarpa R<sup>4</sup>, Tubaro A<sup>5</sup>, Artibani W<sup>6</sup>, Santini A<sup>7</sup>, <sup>1</sup>The FLOW Study Group I<sup>8</sup>, <sup>1</sup>Federico II University, Naples, Italy; <sup>2</sup>S. Maria della Misericordia Hospital, Udine, Italy; <sup>3</sup>Policlinico GB Rossi, Verona, Italy; <sup>4</sup>San Luigi Gonzaga Hospital, Turin, Italy; <sup>5</sup>S. Andrea Hospital, Rome, Italy; <sup>6</sup>University of Padua, Padua, Italy; <sup>7</sup>Boehringer Ingelheim, Milan, Milan, Italy; <sup>8</sup>Italian Urology Centers, Virgilio, Italy

### QL8 QUALITY OF LIFE IN HEMOPHILIC PATIENTS WITHOUT INHIBITORS: THE COCHE STUDY

Scalone L<sup>1</sup>, Gringeri A<sup>2</sup>, Von Mackensen S<sup>3</sup>, Mannucci PM<sup>2</sup>, De Silvio S<sup>1</sup>, Anastasia M<sup>1</sup>, Di Stasi F<sup>1</sup>, Mantovani LG<sup>1</sup>, <sup>1</sup>Center of Pharmacoeconomics, University of Milan, Milan, Italy; <sup>2</sup>Haemophilia and Thrombosis Centre, Milan, Italy; <sup>3</sup>Institute for Medical Psychology, Hamburg, Germany

#### Cost Evaluation Studies In Diabetes And Neurological Disorders

### DN1 ECONOMIC EVALUATION OF SPECT-DATSCAN IN THE DIAGNOSIS OF PATIENTS WITH CLINICALLY UNCERTAIN PARKINSONISM IN ITALY

Busca R<sup>1</sup>, Antonini A<sup>2</sup>, Lopatriello S<sup>3</sup>, Berto P<sup>3</sup>, <sup>1</sup>Pbe Consulting, Milano, Italy; <sup>2</sup>Istituti Clinici di Perfezionamento, Milano, Italy; <sup>3</sup>Pbe consulting, Verona, Italy

### DN2 COST-UTILITY ANALYSIS IN A UK SETTING OF SELF MONITORING OF BLOOD GLUCOSE IN PATIENTS WITH TYPE 2 DIABETES.

Palmer AJ<sup>1</sup>, Dinneen S<sup>2</sup>, Gavin III JR<sup>3</sup>, Gray A<sup>4</sup>, Herman WH<sup>5</sup>, Karter AJ<sup>6</sup>, <sup>1</sup>CORE - Center for Outcomes Research, Binningen, Switzerland; <sup>2</sup>National University of Ireland, Galway, Ireland; <sup>3</sup>Emory University School of Medicine and Morehouse School of Medicine, Fairburn, GA, USA; <sup>4</sup>University of Oxford, Oxford, UK; <sup>5</sup>University of Michigan, Ann Arbor, MI, USA; <sup>6</sup>Kaiser Permanente, Oakland, CA, USA

### DN3 COST-EFFECTIVENESS OF NON-INVASIVE IMAGING IN THE DIAGNOSIS OF PARKINSONISM

Brüggenjürgen B<sup>1</sup>, Smala A<sup>2</sup>, Chambers M<sup>3</sup>, <sup>1</sup>Charité - Universitätsmedizin Berlin, Institut für Sozialmedizin, Epidemiologie und Gesundheitsökonomie, Berlin, Germany; <sup>2</sup>MERG - Medical Economics Research Group, München, Germany; <sup>3</sup>Health Economics, GE Healthcare, Little Chalfont, UK

### DN4 PHARMACOECONOMIC EVALUATION OF SEDATION WITH REMIFENTANIL/PROPOFOL VERSUS MIDAZOLAM/FENTANYL IN THE INTENSIVE CARE UNIT

Muellejans B<sup>1</sup>, Matthey T<sup>1</sup>, Schill M<sup>2</sup>, Welte R<sup>2</sup>, <sup>1</sup>Heart Centre Mecklenburg-Vorpommern, Karlsburg, Germany; <sup>2</sup>GlaxoSmithKline, Munich, Germany

#### Clinical Outcomes Studies

### CO1 VALIDATION OF DIAGNOSTIC PROCEDURES IN SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA. CONCORDANCE BETWEEN INITIAL AND FINAL DIAGNOSIS IN DAILY CLINICAL PRACTICE

Carballido J<sup>1</sup>, Badia X<sup>2</sup>, Gimeno A<sup>3</sup>, Regadera L<sup>4</sup>, Dal-Re R<sup>5</sup>, Guilera M<sup>6</sup>, <sup>1</sup>Hospital Puerta de Hierro, Madrid, Spain; <sup>2</sup>Health Outcomes Research Europe Group, Barcelona, Cataluña, Spain; <sup>3</sup>Hospital General La Mancha, Ciudad Real, Spain; <sup>4</sup>Glaxo Smith Kline, Madrid, Spain; <sup>5</sup>GlaxoSmithKline, Madrid, Spain; <sup>6</sup>Health Outcomes Research Europe, Barcelona, Spain

### CO2 EARLY GLYCEMIC CONTROL IMPROVES HEALTH AND ECONOMIC BENEFITS IN TYPE 2 DIABETES: A MODEL BASED ANALYSIS

Eddy D<sup>1</sup>, Schlessinger L<sup>1</sup>, Parikh S<sup>2</sup>, Patwardhan RN<sup>2</sup>, <sup>1</sup>Kaiser Permanente, Oakland, CA, USA; <sup>2</sup>GlaxoSmithKline, King of Prussia, PA, USA

### CO3 META-REGRESSION ASSESSMENT OF ATOMOXETINE EFFICACY USING RANDOMIZED CONTROLLED ADHD TRIALS

Bae JP, Eli Lilly and Company, Indianapolis, IN, USA

### CO4 A COMPARISON OF LOGISTIC REGRESSION AND COX PROPORTIONAL HAZARDS MODELS FOR IDENTIFICATION OF RISK FACTORS FOR RENAL IMPAIRMENT IN HORMONE REFRACTORY PROSTATE CANCER (HRPC) PATIENTS WITH BONE METASTASES (BM) TREATED WITH ZOLEDRONIC ACID (ZA)

Oh WK<sup>1</sup>, Proctor K<sup>1</sup>, Nakabayashi M<sup>1</sup>, Evan C<sup>1</sup>, Tormey LK<sup>1</sup>, Breierova L<sup>2</sup>, Smith M<sup>2</sup>, Neary M<sup>2</sup>, Duh MS<sup>2</sup>, <sup>1</sup>Dana-Farber Cancer Institute, Boston, MA, USA; <sup>2</sup>Analysis Group Inc, Boston, MA, USA; <sup>3</sup>F. Hoffmann-La Roche, Ltd, Basel, Switzerland

15:30-15:45 **Break Coffee Sponsored by: Caro Research** 

### 15:45-16:45 ISSUES PANELS - SESSION I

#### IP1: PAYOR ORIENTED EVIDENCE GUIDELINES

**Moderator:** Joseph Singer MD, Integrated Research Network, HealthCore, Inc, Wilmington, DE, USA  
**Panelists:** James MacKay MD, Providence Health Plan, Beaverton, OR, USA

#### IP2: MEMORY AND PERCEPTION: THE ISSUE OF RECALL BIAS IN PATIENT-REPORTED OUTCOMES

**Moderator:** Laurie Burke RPh, MPH, Food and Drug Administration, Rockville, MD, USA  
**Panelists:** Donald E. Stull PhD, The MEDTAP Institute at UBC, Bethesda, MD, USA; Olivier Chassany, Hopitaux de Paris Hôpital Saint-Louis, Paris, France

#### IP3: SUBMISSION OF PATIENT-REPORTED OUTCOMES TO THE EMEA AND THE FDA: AREAS OF CONVERGENCE OR DIVERGENCE

**Moderator:** Patrick Marquis MBA, MD, Mapi Values, Boston, MA, USA  
**Panelists:** Laurie Burke RPh, MPH, Food and Drug Administration, Rockville, MD, US;  
Giovanni Apolone MD, Mario Negri Institute, Milan, Italy

#### IP4: PROGRESS AND UNCERTAINTY IN HEALTH TECHNOLOGY ASSESSMENT

**Moderator:** Frank Papatheofanis MD, MPH, PhD, University of California San Diego, San Diego, CA, USA  
**Panelists:** Uwe Siebert MD, MPH, MSc, Cardiovascular Research Program, Harvard Medical School, Boston, MA, USA

#### IP5: EVALUATION OF DRUG SAFETY: CAN THE USE OF HEALTH ECONOMICS AND OUTCOMES RESEARCH (HEOR) METHODS PRODUCE BETTER DECISIONS?

**Moderator:** John Hutton BPhil, United BioSource Corporation, London, UK  
**Panelists:** Francis Pang MSc, PhD, Abbott Laboratories Ltd, Maidenhead, Berkshire, UK;  
Clive Pritchard PhD, Office of Health Economics, London, UK

16:45-17:00 **Break Coffee Sponsored by: Caro Research** 

### 17:00-18:00 ISPOR FORUMS

#### ISPOR EUROPEAN MEDICAL DEVICE AND DIAGNOSTICS COUNCIL FORUM - WHEN AND HOW TO ASSESS MEDICAL DEVICE AND DIAGNOSTICS: THE LEARNING CURVE ISSUE

**Moderator:** Rod Taylor MSc, PhD, Senior Reader in Public Health & Epidemiology & Director of MSC HTA Programme, Department of Public Health & Epidemiology, University of Birmingham, Edgbaston, Birmingham, UK

**Speakers:** Patrick Galloo MD, Geneesheer - Directeur, National Alliance of Social Sickness Funds, Brussels, Belgium; Claire Parker (invited), Horizon Scanning Centre, Birmingham, UK; and Karen Talmadge (invited), Chief Scientific Officer and Co-Founder, Kyphon Inc., Zaventem, Belgium

#### ISPOR RUSSIA CHAPTER FORUM - THE REIMBURSEMENT SYSTEM DEVELOPMENT AND RATIONAL USE OF DRUGS

**Moderator:** Pavel Vorobiev MD, Professor, Moscow Medical Academy named after Sechenov, Head of the Research Department on Health Care Standardization Problems, Moscow, Russia

**Speakers:** Representative of the Federal Service on Surveillance under Health Care and Social Development; ISPOR Representative; Russian Regional Health Care Leader

#### ISPOR MEDICATION COMPLIANCE / PERSISTENCE SPECIAL INTEREST GROUP

**Moderator:** Joyce Cramer BS, Medication Compliance & Persistence SIG Chair & Associate Research Scientist, Yale University School of Medicine, Department of Psychiatry, West Haven, CT, USA

## ISPOR REAL WORLD DATA IN COVERAGE AND REIMBURSEMENT DECISIONS TASK FORCE-REAL WORLD DATA TASK FORCE REPORT

**Moderators: Task Force Co-Chairs:** Peter Neumann ScD, Associate Professor of Policy and Decision Sciences, Harvard School of Public Health, Boston, MA, USA, and Lou Garrison PhD, Professor, Department of Pharmacy, University of Washington, Seattle WA, USA

## ISPOR BUDGET IMPACT TASK FORCE

**Moderators: Task Force Co-Chairs:** Josephine Mauskopf PhD, VP, Health Economics, RTI Health Solutions, RTI International, Research Triangle Park, NC, USA; Sean Sullivan MS, PhD, RPh, Professor and Director, University of Washington, Pharmaceutical Outcomes Research and Policy Program, Seattle, WA, USA

**Speakers:** Lieven Annemans MSc, PhD, Health Economist Ghent University, Senior Consultant Global Health Economics, HEDM and IMS Health, Brussels, Belgium; J. Jaime Caro MD, Scientific Director, Caro Research, Concord, MA, USA; C. Daniel Mullins PhD, Professor and Chair, Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD, USA; Mark Nuijten MBA, MD, PhD, Sr. Research Scientist, Dir. of Business Dev., MEDTAP International, Inc., Jisp, The Netherlands; Ewa Orlewska PhD, Lecturer, Pharmacoeconomics Centre Warsaw, Warsaw; Paul Trueman MA, Sales & Marketing Director, York Health Economics Consortium, University of York, York, UK; Andrew Wilson BMedSc, MB SC, FRACP, MSc, Deputy Director and Professor of Public Health, University of Queensland, School of Public Health, Brisbane, Australia

## 18:00-20:00 EXHIBITORS' WINE & CHEESE RECEPTION & POSTER PRESENTATIONS - SESSION II & ISPOR 10TH ANNIVERSARY CELEBRATION



## 20:15-23:30 ISPOR 10th ANNIVERSARY PARTY AT THE VINCIGLIATA CASTLE Feisole, Italy (Registration Required)

# TUESDAY, 8 NOVEMBER 2005

## 8:00-9:00 CONTRIBUTED RESEARCH POSTER PRESENTATIONS - SESSION III VIEWING (Over 200 posters)

## 9:00-10:30 THIRD PLENARY SESSION - THE VALUE OF SAFETY: A CRITICAL ISSUE ALONG THE DEVELOPMENT AND MARKETING OF PHARMACEUTICALS

This plenary session will address the recent experiences of some important drugs which were withdrawn from the market due to AE's, but also to prompt considerations and comments regarding delays in bringing new products to market because of the need for more safety data.

**Speakers:** Prof. Achille Caputi, Istituto Farmacologia, School of Medicine, Università di Messina, Policlinico Universitario, Messina, Italy; Prof. Bruno Stricker MD, PhD, Professor, Pharmacoeconomics, Department of Epidemiology and Biostatistics, Erasmus Medical Center, Rotterdam, The Netherlands

## 10:30-10:45 Break Coffee sponsored by RTI Health Solutions

## 10:45-11:45 ISSUES PANELS - SESSION II

### IP6: DO VACCINES RAISE ADDITIONAL ANALYTIC OR POLICY CHALLENGES?

**Moderator:** Jeremy Chancellor MSc, Innovus Research (UK) Ltd, High Wycombe, Buckinghamshire, UK  
**Panelists:** Michael Drummond PhD, Innovus Research (UK) Ltd, High Wycombe, UK; Joel Calmet MD, MS, Aventis Pasteur SA, Lyon, France; Elizabeth Miller OBE, BSc, MB BS, FRCP, FFPHM, Immunisation Department, Health Protection Agency, Communicable Disease Surveillance Centre, London, UK

### IP7: DO WE REALLY KNOW THE DIFFERENCE BETWEEN PROS AND QOL AND WHY IT'S IMPORTANT?

**Moderator:** Olivier Chassany, Hopitaux de Paris Hôpital Saint-Louis, Paris, France  
**Panelists:** Laurie Burke RPh, MPH, Food and Drug Administration, Rockville, MD, US; Richard Wilke PhD, Global Outcomes Research, Pfizer Inc, Bridgewater, NJ, USA; Pennifer Erickson PhD, O.L.G.A., State College, PA, USA

### IP8: 'FOURTH HURDLE' SYSTEMS: HOW WELL ARE THEY USING HTA IN DECISION-MAKING?

**Moderator:** Martin Buxton, Brunel University, Uxbridge, Middx, UK  
**Panelists:** Chris Henshall PhD, University of York, York, UK; Clare McGrath BS, Pfizer Ltd, Tadworth, Surrey, UK; John Hutton BSc, BPhI, United BioSource Corporation, London, UK

### IP9: THE QUALITY OF PHARMACO-ECONOMIC REIMBURSEMENT DOSSIERS

**Moderator:** Ralph Crott MPH, PhD, Centre Fédéral d'Expertise des Soins de Santé, Bruxelles, Belgium  
**Panelists:** Anemarie Jansen PhD, Health Care Insurance Board (CVZ), Diemen, The Netherlands; Andreas Engstrom, Pharmaceutical Benefits Board, Solna, Sweden; Peter Wieninger MSc, Hauptverband der Österreichischen Sozialversicherungsträger, Vienna, Austria; Karen Lee MA, CCOHTA, Ottawa, Ontario, Canada

## 11:45-13:30 LUNCH, EXHIBITS & CONTRIBUTED RESEARCH POSTER PRESENTATIONS-SESSION III (Over 200 posters)

Lunch Sponsored by The MEDTAP Institute at UBC

## 13:30-14:30 CONTRIBUTED WORKSHOPS-SESSION III

### W17: THE USE OF HISTORICAL CONTROLS TO ENABLE ACTUAL PRACTICE COMPARISONS FOR PROSPECTIVE OBSERVATIONAL STUDIES

**DL:** J. Jaime Caro MD, Caro Research Institute, Concord, MA, USA; Zeba Khan PhD, Novartis Pharma AG Basel, Switzerland; William Daley MD, MPH, Novartis Pharmaceuticals Corp East Hanover, NJ, USA; Krista Payne MEd, HECON Study Design and Data Capture, Caro Research Institute Montreal, QC, Canada

### W18: DEVELOPING A CURRICULUM FOR MEDICATION COMPLIANCE USING CURRICULUM MAPPING STRATEGY

**DL:** Hieu Tran PharmD, Department of Pharmacy Practice, Lake Erie College of Osteopathic Medicine,

Erie, PA, USA; Andrea Adamus PhD, RPh, Department of Pharmaceutical Policy & Outcomes Research, U.T. M.D. Anderson Cancer Center, Houston, TX, USA; Jasminda Wu PhD, Global Pharmacovigilance and Epidemiology, Sanofi-Aventis Pharmaceutical, Bridgewater, NJ, USA

### W19: CALCULATING STUDY POWER FOR ECONOMIC ANALYSES ALONGSIDE CLINICAL TRIALS

**DL:** Elinor CG Chumney PhD, MSc, Department of Pharmacy and Clinical Science, Medical University of South Carolina, Charleston, SC, USA; Kit N Simpson DrPH, Health Administration and Policy, Medical University of South Carolina, College of Health Professions, Charleston, SC, USA

### W20: GLOBAL PRICING AND REIMBURSEMENT STRATEGY: AN INTEGRATED ANALYTICAL FRAMEWORK

**DL:** Keiron Sparrowhawk MSc, MBA, PriceSpective Ltd, Buntingford, UK; Deirdre M Mladsji BA, Health Outcomes Strategy, RTI Health Solutions, Research Triangle Park, NC, USA; Nigel Gregson BA, PriceSpective LLC, Bluebell, PA, USA

### W21: PHARMACOECONOMICS AND MARKET ACCESS IN EUROPE: CASE STUDIES IN SCOTLAND AND THE NETHERLANDS

**DL:** KH Tolley MPhil, Mapi Values, Bollington, Cheshire, UK; Maarten J Postma Dr, Groningen University Institute for Drug Exploration, Groningen, The Netherlands

### W22: UNDERSTANDING INTERNATIONAL REQUIREMENTS WHEN DEVELOPING AND IMPLEMENTING A GLOBAL PATIENT REGISTRY: STRATEGIES TO MAXIMIZE SUCCESS

**DL:** Matthew J Gordon BA, Ovation Research Group, Highland Park, IL, USA; Alison Wetherfield JD, Employment Department, McDermott Will & Emery, London, UK; Leanne Larson MPH, Patient Registries, Ovation Research Group, Highland Park, IL, USA

### W23: INTERNATIONAL ECONOMIC EVALUATIONS OF IMMUNISATION POLICIES: COMPARABILITY OF RESULTS AND CONCLUSIONS

**DL:** Ursula M Kuehnel MSc, Health Economics, Berna Biotech, Bern, Switzerland; Jeremy Chancellor MSc, Innovus Research (UK) Ltd, High Wycombe, Buckinghamshire, UK; Michael Drummond PhD, Innovus Research (UK) Ltd, High Wycombe, UK

### W24: RESCUING CLINICAL TRIAL DATA FOR ECONOMIC EVALUATION

**DL:** Frank De Charro, EuroQoL Group, Erasmus University Rotterdam, Centre for Health Policy and Law, Rotterdam, The Netherlands; Xavier Badia MD, PhD, Health Outcomes Research Europe, Barcelona, Spain; Wolfgang Greiner MSc, Fakultät fuer Gesundheitswissenschaften, Bielefeld University, Bielefeld, Germany; Paul Kind MPhil, Centre for Health Economics, Outcomes Research Group, University of York, York, UK

## 14:30-14:45 Break Coffee sponsored by RTI Health Solutions

## 14:45-15:45 CONTRIBUTED RESEARCH PODIUM PRESENTATIONS - SESSION IV (16 presentations)

### Development And Application Of Methods And Concepts In Statistics For Outcomes Research

#### MC5 ON EVALUATING COST ASSOCIATED WITH EVENT-CENSORED DATA: APPLICATION TO ALL-CAUSE GRAFT FAILURE FOLLOWING KIDNEY TRANSPLANTATION

Irish WD, Wang J, RTI Health Solutions, Research Triangle Park, NC, USA

#### MC6 PERFORMANCE OF THE DMM SIMULATION MODEL IN PREDICTING REAL WORLD CHANGES IN GLYCEMIC CONTROL FOLLOWING DIAGNOSIS OF DIABETES

James PW, MacAlpine R, Brennan G, Emslie-Smith A, Morris AD, Ninewells Hospital and Medical School, Dundee, UK

#### MC7 THE PHARMACOGONOMICS BIAS IN DECISION MODELS

Siebert U<sup>1</sup>, Goldie SJ<sup>2</sup>, Weinstein MC<sup>3</sup>, Kuntz KM<sup>2</sup>, <sup>1</sup>Harvard Medical School, Boston, MA, USA; <sup>2</sup>Harvard School of Public Health, Boston, MA, USA; <sup>3</sup>Harvard Center for Risk Analysis, Boston, MA, USA

#### MC8 THE APPLICATION OF BAYESIAN METHODS TO EVALUATE THE IMPACT OF TIME-DELAY ON THE COST-EFFECTIVENESS OF PRIMARY ANGIOPLASTY FOR ACUTE MYOCARDIAL INFARCTION

Palmer SJ, Asseburg C, Bravo-Vergel J, Fenwick E, Sculpher M, University of York, York, North Yorkshire, UK

### Preference And Utility Based Patient Reported Outcomes

#### PR1 EVALUATION OF PREFERENCES IN GENITAL HERPES TREATMENT USING A DISCRETE CHOICE EXPERIMENT

Scalone L<sup>1</sup>, Watson V<sup>2</sup>, Ryan M<sup>2</sup>, Kotsopoulos N<sup>3</sup>, Patel R<sup>4</sup>, <sup>1</sup>Center of Pharmacoeconomics, University of Milan, Milan, Italy; <sup>2</sup>Health Economics Research Unit, University of Aberdeen, Aberdeen, UK; <sup>3</sup>GlaxoSmithKline, Brentford, UK; <sup>4</sup>Department of Genito Urinary Medicine, Royal South Hampshire Hospital, Southampton, UK

#### PR2 PERCEIVED UTILITY OF HEALTH STATES INDUCED BY CHRONIC HEPATITIS B: ESTIMATES FROM UNINFECTED PERSONS IN CANADA

Levy A<sup>1</sup>, Tafesse E<sup>2</sup>, Mukherjee J<sup>2</sup>, Iloeje U<sup>3</sup>, Poissant L<sup>4</sup>, Briggs A<sup>5</sup>, <sup>1</sup>Oxford Outcomes, Vancouver, Bristis Columbia, Canada; <sup>2</sup>BMS, Wallingford, CT, USA; <sup>3</sup>Bristol-Myers Squibb Company, Wallingford, CT, USA; <sup>4</sup>McGill University, Montreal, QC, Canada; <sup>5</sup>University of Glasgow, Glasgow, UK

#### PR3 BIPOLAR PATIENTS' STATED THERAPY PREFERENCES AND LIKELY ADHERENCE

Johnson FR<sup>1</sup>, Özdemir S<sup>1</sup>, Manjunath R<sup>2</sup>, Burch SP<sup>2</sup>, <sup>1</sup>Research Triangle Institute, Research Triangle Park, NC, USA; <sup>2</sup>GlaxoSmithKline, Research Triangle Park, NC, USA

#### PR4 PATIENT PREFERENCE AND WILLINGNESS-TO-PAY FOR ANTICOAGULANT TREATMENT OPTIONS IN PATIENTS RECEIVING ORAL ANTICOAGULANT TREATMENT (OAT): A CONJOINT ANALYSIS EXERCISE

Monzini M<sup>1</sup>, Carpenedo M<sup>2</sup>, Moia M<sup>2</sup>, Mantovani LG<sup>1</sup>, <sup>1</sup>Center of Pharmacoeconomics, Milan, Italy; <sup>2</sup>IRCCS Maggiore Hospital and University of Milan, Milan, Italy

### Cost Evaluation Studies In Infectious Diseases

#### IN1 COSTS ASSOCIATED WITH SHORTER DURATION OF ANTIBIOTIC THERAPY IN HOSPITALIZED PATIENTS WITH COMMUNITY-ACQUIRED PNEUMONIA

Opmeer BC, el Moussaoui R, Bossuyt PM, Speelman P, Prins JM, deBorgie CA, Academic Medical Center/University of Amsterdam, AMSTERDAM, Noord-Holland, The Netherlands

#### IN2 ASSESSMENT OF THE ADDITIONAL COST OF DROTRECOGIN ALFA (ACTIVATED) RELATIVE TO STANDARD CARE IN THE TREATMENT OF SEVERE SEPSIS IN A MULTICENTRIC OBSERVATIONAL STUDY IN FRANCE

Payet S<sup>1</sup>, Riou Frana L<sup>1</sup>, Le Lay K<sup>1</sup>, Dhainaut JF<sup>2</sup>, Vallet B<sup>3</sup>, Launois R<sup>1</sup>, REES France, Paris, France; <sup>1</sup>UNIVERSITE PARIS V, Paris, France; <sup>2</sup>HOPITAL CLAUDE HURIEZ, Lille, France

#### IN3 COST-EFFECTIVENESS OF VORICONAZOLE VERSUS LIPOSOMAL AMPHOTERICIN B FOR INVASIVE ASPERGILLOSIS INFECTION IN THE UK

Mesrobian X<sup>1</sup>, Loftus J<sup>2</sup>, Roberts C<sup>3</sup>, Jansen J<sup>4</sup>, Mapi Values USA, Boston, MA, USA; <sup>1</sup>Pfizer, Tadworth, Surrey, UK; <sup>2</sup>Pfizer Inc, New York, NY, USA; <sup>3</sup>MAPI VALUES, Houten, The Netherlands

#### IN4 LOWERING THE AGE THRESHOLD FOR ROUTINE INFLUENZA VACCINATION: AN ECONOMIC EVALUATION FOR FOUR EUROPEAN COUNTRIES

Aballea S<sup>1</sup>, Chancellor J<sup>1</sup>, Martin M<sup>1</sup>, Wutzler P<sup>2</sup>, Carrat F<sup>3</sup>, Gasparini R<sup>4</sup>, De Juanes JR<sup>5</sup>, Drummond M<sup>1</sup>, <sup>1</sup>Innovus Research (UK) Ltd, High Wycombe, UK; <sup>2</sup>Friedrich-Schiller-Universitat, Jena, Germany; <sup>3</sup>INSERM, Paris, France; <sup>4</sup>Universit degli studi di Genova, Genova, Italy; <sup>5</sup>Hospital 12 de Octubre, Madrid, Spain

#### Cost Evaluation Studies In Cancer

#### CN1 COST-EFFECTIVENESS ANALYSIS OF OXALIPLATIN/5-FU/LV IN ADJUVANT TREATMENT OF STAGE III COLON CANCER IN THE UK AND GERMANY

Aballea S<sup>1</sup>, Chancellor J<sup>1</sup>, Raikou M<sup>2</sup>, Drummond M<sup>1</sup>, Diel R<sup>3</sup>, Frick M<sup>4</sup>, Rosenfeld S<sup>5</sup>, Boler A<sup>6</sup>, Jourdan S<sup>7</sup>, Paulo C<sup>8</sup>, Bridgewater J<sup>9</sup>, <sup>1</sup>Innovus Research (UK) Ltd, High Wycombe, Buckinghamshire, UK; <sup>2</sup>London School of Economics, London, UK; <sup>3</sup>Heinrich-Heine-Universitt, Dusseldorf, Germany; <sup>4</sup>Aventis Pharma Deutschland GmbH, Berlin, Germany; <sup>5</sup>Heron Evidence Development, Letchworth Garden City, UK; <sup>6</sup>Sanofi-Aventis R&D, Bagneux, France; <sup>7</sup>Royal Free & University College Medical School, London, UK

#### CN2 COST-EFFECTIVENESS OF TEMOZOLOMIDE FOR THE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME IN THE UK

Uyl-de Groot C<sup>1</sup>, Lamers LM<sup>1</sup>, Al M<sup>1</sup>, Bent van den M<sup>2</sup>, Gorlia T<sup>3</sup>, Crott R<sup>4</sup>, Mason W<sup>5</sup>, Stupp R<sup>6</sup>, <sup>1</sup>Erasmus MC, university medical center Rotterdam, Rotterdam, The Netherlands; <sup>2</sup>Erasmus MC, Rotterdam, The Netherlands; <sup>3</sup>EORTC, Brussels, Belgium; <sup>4</sup>Centre Fdral d'Expertise des Soins de Sant, Bruxelles, Belgium; <sup>5</sup>Princess Margaret Hospital, Toronto, Ontario, Canada; <sup>6</sup>University of Lausanne Hospitals, Lausanne, Switzerland

#### CN3 HEALTH ECONOMIC EVALUATION BASED ON THE 5-YEAR COMPLETED TREATMENT ANALYSIS OF THE ATAC TRIAL COMPARING ANASTROZOLE VERSUS TAMOXIFEN IN ADJUVANT TREATMENT OF POST-MENOPAUSAL HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER

Moeremans K, Annemans L, IMS Health, Brussels, Belgium

#### CN4 COST MINIMISATION ANALYSIS OF FIRST LINE POLYCHEMOTHERAPY REGIMENS IN THE TREATMENT OF ADVANCED NON SMALL CELL LUNG CANCER

Launois R<sup>1</sup>, Le Lay K<sup>1</sup>, Riou Frana L<sup>1</sup>, Avoinet S<sup>2</sup>, Chemali N<sup>3</sup>, Vergnenegre A<sup>4</sup>, REES France, Paris, France; <sup>1</sup>Lilly, Suresnes Cedex, France; <sup>2</sup>CHU Dupuytren, Limoges, France

#### 16:00-17:00 CONTRIBUTED WORKSHOPS- SESSION IV

#### W25: CHALLENGES OF DESIGNING PROSPECTIVE AND RETROSPECTIVE COMPLIANCE STUDIES

DL: Won Chan Lee PhD, HERQuLES, Abt Associates, Bethesda, MD, USA; Asli Memisoglu ScD,

HERQuLES, Abt Associates, Lexington, MA, USA; Chris L Pashos PhD, HERQuLES, Abt Associates, Lexington, MA, USA

#### W26: DRG-BASED CASE COSTS: WHY THEY ARE NOT COMPARABLE ACROSS BORDERS AND SHOULD BE USED WITH CAUTION

DL: Judith A. O'Brien RN, BSPA, Caro Research Institute, Concord, MA, USA

#### W27: METHODOLOGICAL CHALLENGES FOR COST-EFFECTIVENESS STUDIES FOR MEDICAL DEVICES

DL: Mark JC Nuijten PhD, MD, MBA, Erasmus University, Rotterdam, The Netherlands

#### W28: KEY ISSUES IN MARKET ACCESS: UK, SWEDEN, AND GERMANY

DL: Pippa Anderson MSc, Fourth Hurdle Consulting Limited, London, UK; Emma Bloomfield MBA, Fourth Hurdle Consulting Limited, London, UK; David Grant MBA, Fourth Hurdle Consulting Limited, London, UK; Ulf Persson PhD, IHE, The Swedish Institute for Health Economics, Lund, Sweden; Anders Anell PhD, The Swedish Institute for Health Economics, Lund, Sweden; Bernd Bruggenjrgen MD, MPH, Charit - Universittsmedizin Berlin, Institut fr Sozialmedizin, Epidemiologie und Gesundheitskonomie, Berlin, Germany; Joerg Burkowitz MPH, Alpha Care GmbH, Celle, Germany

#### W29: INTRODUCTION AND DIFFUSION OF INNOVATIVE INPATIENT DRUGS. COMBATING INEQUALITIES

DL: Eily Stolk PhD, Institute Medical Technology Assessment, Erasmus University, Rotterdam, The Netherlands; Floor Nooten van PhD, Institute for Medical Technology Assessment, Erasmus University, Rotterdam, The Netherlands; Carin Uyl PhD, Institute of medical Technology Assessment, Erasmus University, Rotterdam, The Netherlands; Mark JC Nuijten PhD, MD, MBA, Erasmus University, Rotterdam, The Netherlands; Martijn T Groot MSc, Institute for Medical Technology Assessment, Erasmus University, Rotterdam, The Netherlands

#### W30: THE VALUE OF CONJOINT ANALYSIS IN OUTCOMES RESEARCH

DL: JP Jansen PhD, Health Economics, MAPI Values, Houten, The Netherlands; KH Tolley MPhil, Mapi Values, Adelphi Mill, Bollington, UK; Elyse Trudeau PhD, MAPI Values, Lyon, France

#### W31: HEALTH STATUS AND QUALITY OF LIFE ASSESSMENT FOR CRITICAL DECISION MAKERS - CLINICIANS, ADMINISTRATORS AND HEALTH ECONOMISTS

DL: Pennifer Erickson PhD, O.L.G.A., State College, PA, USA; Nancy Kliene Leidy PhD, The MEDTAP Institute at UBC, Bethesda, MD, USA; Margaret Rothman PhD, HE&P, PGSM, Johnson & Johnson Pharmaceutical Services, Raritan, NJ, USA

#### W32: RISK ADJUSTMENT IN NON-COMPETITIVE MARKETS

DL: Kenneth D. Smith PhD, Department of Health Policy, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA, USA; Vittorio Maio PharmD, MSPH, Department of Health Policy, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA, USA; Elaine J. Yuen PhD, MBA, Center for Research in Medical Education and Health Care, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA, USA; Daniel Z. Louis MS, Center for Research in Medical Education and Health Care, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA, USA

\* DL = Discussion Leaders

**ACPE Continuing Education:** For pharmacists (CPE): Continuing Education credits for pharmacists will be provided by Trinka Medical Publications. Attendees can earn a certain number of hours (or CEUs) for attending Issues Panels, Forums, Plenary Sessions, Workshops, and Podium Sessions at the Annual Meeting, and up to 4 hours (0.4 CEUs) for each half day short course, and 7.5 hours (0.75 CEUs) for each full day short course. Trinka Medical Publications is approved by the Accreditation Council for Pharmacy Education as a provider of continuing pharmaceutical education. To receive continuing education credit, obtain the Continuing Education Program Summary Booklet at the ISPOR registration desk OR register online at [www.ispor.org](http://www.ispor.org). The fee for this service is \$30 USD.



## Congress Promotional Opportunities:

### EXHIBIT

Take part in the ISPOR Exhibit Program! Present your products and services to key outcomes researchers and health care decision-makers in pharmaceutical and biotechnology industries, clinical practice, government agencies, academia, and managed care organizations.

#### Benefits for Exhibitors:

- One complimentary registration
- Listing and 1/4 page ad on the ISPOR website
- Listing and 1/4 page ad in the Program & Schedule of Events

### SPONSOR

Becoming an event sponsor is a great promotional opportunity. Give your company name increased visibility and reach out to the most influential decision-makers in health care outcomes economics.

#### Benefits for Sponsors:

- One complimentary registration (for opportunities over \$3000)
- Recognition at Plenary Session
- Recognition with Congress signage and balloons
- Listing and 1/4 page ad on the ISPOR website
- Listing and 1/4 page ad in the Program & Schedule of Events

### ADVERTISE

Advertise your products and services in the ISPOR 8th Annual European Congress Program & Schedule of Events.

**ALL ADVERTISEMENTS MUST BE RECEIVED BY 14 SEPTEMBER 2005 TO BE INCLUDED IN THE PROGRAM & SCHEDULE OF EVENTS**

**CORPORATE SPONSORS (TO DATE):** NOVARTIS • MERCK & CO • WYETH RESEARCH • F. HOFFMAN-LA ROCHE • ASTRAZENACA • GSK  
**EVENT SPONSORS (TO DATE):** AEQUITAS • CARO RESEARCH • THE MEDTAP INSTITUTE AT UBC • RTI HEALTH SOLUTIONS

For more information about becoming a sponsor for this Congress contact: [eventsponsor@ispor.org](mailto:eventsponsor@ispor.org)

## Professional Recruitment Center (PRAP):

**Employers:** Post your positions at the ISPOR PRAP Employment Center (Professional Recruitment Assistance Program) and reach the most qualified individuals in health economics, quality of life and other outcomes research fields. **Benefits:** FREE listing and 1/4 page ad in the final program

• Position listing on the ISPOR website • On site mailbox to communicate with candidates • Interview room **Candidates:** Enhance your career and meet your future employers. View and apply for available positions during the Congress. **Bring your CV.** **Opening Hours:** Sunday 12:00-18:00; Monday 8:00-18:00; Tuesday 8:00-17:00 [www.ispor.org/prap.asp](http://www.ispor.org/prap.asp)



For detailed Congress and promotional information, visit the ISPOR website: [www.ispor.org](http://www.ispor.org)

# ISPOR 8<sup>TH</sup> ANNUAL EUROPEAN CONGRESS REGISTRATION

## 6-8 NOVEMBER 2005 | PALAZZO DEGLI AFFARI | FLORENCE, ITALY

please print clearly

ISPOR Member ID# \_\_\_\_\_

|                       |             |                    |               |
|-----------------------|-------------|--------------------|---------------|
| NAME _____            |             | DEGREES _____      |               |
| POSITION _____        |             | ORGANIZATION _____ |               |
| MAILING ADDRESS _____ |             |                    |               |
| CITY _____            | STATE _____ | ZIP _____          | COUNTRY _____ |
| TELEPHONE _____       | FAX _____   | EMAIL _____        |               |

### ISPOR SHORT COURSE REGISTRATION

#### SATURDAY, 5 NOVEMBER 2005

MORNING SESSIONS 9:00-13:00 AFTERNOON SESSIONS 14:00-18:00

##### Pharmacoeconomic/Economic Methods

Pharmacoeconomics (all day course)

##### QOL/PRO/Preference-based Methods

QOL/PRO Analysis

##### Real World Data Methods

EU Databases & Retrospective

Analyses

##### Pharmacoeconomic/Economic Methods

Cost Estimation

##### Modeling

Pharmacoeconomic Modeling

#### SUNDAY, 6 NOVEMBER 2005

MORNING SESSIONS 8:00-12:00

##### QOL/PRO/Preference-based Methods

Utility Measurements

##### Use of PE/Econ/OR Information

EU Reimbursement Systems

##### Pharmacoeconomic/Economic Methods

Pharmaceutical Pricing

##### Pharmacoeconomic/Economic Methods

Data Transferability

##### Modeling

Bayesian Methods

##### Modeling

Discrete Event Stimulation

#### SHORT COURSE REGISTRATION FEES

##### HALF DAY COURSES

###### BEFORE 4 OCTOBER 2005

US\$150 125 € REGULAR FEE

US\$75 62 € STUDENT FEE

###### AFTER 4 OCTOBER 2005

US\$200 166 € REGULAR FEE

US\$100 85 € STUDENT FE

##### FULL DAY COURSES

###### BEFORE 4 OCTOBER 2005

US\$300 249 € REGULAR FEE

US\$150 125 € STUDENT FEE

###### AFTER 4 OCTOBER 2005

US\$400 332 € REGULAR FEE

US\$200 166 € STUDENT FEE

### ISPOR ANNIVERSARY PARTY AT VINCIGLIATA CASTLE

Monday, 7 November, 20:00 (wine tasting, dinner buffet, music, dancing, transportation) US\$100 85 €

### ISPOR CONGRESS REGISTRATION

exchange rate as of July 2005

ISPOR Member Non-Member\*

#### Standard

Registration Before 4 October  US\$600 498 €  US\$740 614 €

Registration After 4 October  US\$700 581 €  US\$840 697 €

#### Clinical Practitioners (Clinical Practice, Hospital)

Registration Before 4 October  US\$450 374 €  US\$590 490 €

Registration After 4 October  US\$550 457 €  US\$690 573 €

#### Full-Time Government and Academia

Registration Before 4 October  US\$300 249 €  US\$440 365 €

Registration After 4 October  US\$400 332 €  US\$540 448 €

ISPOR Member Non-Member\*

#### Full-Time Students (must provide current enrollment documentation)

Registration Before 4 October  US\$100 85 €  US\$135 112 €

Registration After 4 October  US\$150 125 €  US\$185 154 €

#### One Day Registration (per day)\*\* (One Day registrations cannot be combined)

6 Nov  7 Nov  8 Nov  US\$350 291 €  US\$400 332 €

Continuing Education Accreditation  US\$30 25 €  US\$30 25 €

### REGISTRATION FEES

|                                    | QTY | FEE | TOTAL |
|------------------------------------|-----|-----|-------|
| Short Course Full Day Registration |     |     |       |
| Short Course Half Day Registration |     |     |       |
| ISPOR Anniversary Party            |     |     |       |
| Congress Registration              |     |     |       |

**TOTAL REGISTRATION FEE:**

### PAYMENT INFORMATION

Please enclose a check payable in US dollars or Euro € to: International Society for Pharmacoeconomics and Outcomes Research or ISPOR and send to the ISPOR address given below

or charge to:  VISA  MasterCard  American Express ACCOUNT NUMBER: \_\_\_\_\_ EXPIRATION DATE: \_\_\_\_\_

NAME: \_\_\_\_\_ AUTHORIZED SIGNATURE: \_\_\_\_\_

**Mail Details:** If not paying by credit card online, send registration form and payment to:  
International Society for Pharmacoeconomics and Outcomes Research, 3100 Princeton Pike,  
Building 3 Suite E, Lawrenceville, New Jersey 08648, USA  
Tel: 1-609-219-0773 • Fax: 1-609-219-0774 • E-Mail: info@ispor.org • Internet: www.ispor.org

**Payment Details:** Payment may be made by check, travelers check, bank transfer (there is a USD \$40 charge) or credit card. VISA, MasterCard, or American Express will be charged in US dollars. Signature, account number and expiration date must be included. Non-US checks written in US\$ on banks with a US counterpart are at no charge. For Non-US checks written in US\$ on banks with NO US counterpart there is USD \$25 charge. Phone charges will NOT be accepted.  
**If payment is being made by your company, please make sure your name is indicated on**

**the check stub or correspondence. For Bank transfers, please designate the registration name and/or registration number.**

#### Membership Details:

- If ISPOR cannot verify your current membership, you will be charged the non-member registration rate.
- When you register as a non-member, you receive ISPOR membership which includes a one year online subscription to VALUE IN HEALTH - The Journal of the International Society for Pharmacoeconomics and Outcomes Research.
- One Day registration does not include ISPOR membership benefits and cannot be combined.

**Cancellation Details:** Cancellation fee before 4 October 2005 is US \$100. No refunds given after 4 October 2005.

Online registration available at [www.ispor.org](http://www.ispor.org)